University Regional General Hospital of Patras, is a public general Hospital located next to the University of Patras in Rio, Greece, just few kilometers away from the city of Patras.The construction of the hospital was completed in 1988 and a few months later it began operation.

There are 800 beds in University Hospital of Patras Medical Oncology.

During the past decade, University Hospital of Patras Medical Oncology conducted 91 clinical trials. In the 10-year time frame, 91 clinical trials started and 33 clinical trials were completed, i.e. on average, 36.3% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 25 clinical trials were completed. i.e. 64.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital of Patras Medical Oncology" #1 sponsor was "University of Patras" with 29 trials, followed by "Hoffmann-La Roche" with 23 trials sponsored, "University Hospital of Patras" with 20 trials sponsored, "Hellenic Institute for the Study of Sepsis" with 7 trials sponsored and "Boehringer Ingelheim" with 7 trials sponsored. Other sponsors include 48 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital of Patras Medical Oncology" #1 collaborator was "University Hospital of Patras" with 4 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "AHEPA University Hospital" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Australasian Leukaemia and Lymphoma Group" with 1 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital of Patras Medical Oncology" are "Coronary Artery Disease" (9 trials), "Acute Coronary Syndrome" (4 trials), "Breast Cancer" (4 trials), "COVID-19" (4 trials) and "Platelet Reactivity" (4 trials). Many other conditions were trialed in "University Hospital of Patras Medical Oncology" in a lesser frequency.

Most popular intervention types in "University Hospital of Patras Medical Oncology" are "Drug" (96 trials), "Procedure" (12 trials), "Device" (9 trials), "Other" (9 trials) and "Diagnostic Test" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Atezolizumab" (9 trials), "Ticagrelor" (9 trials), "Prasugrel" (7 trials) and "Docetaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital of Patras Medical Oncology" are 129 trials for "All" genders, 5 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "University Hospital of Patras Medical Oncology". 1 are not yet recruiting, 18 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 88 completed trials in University Hospital of Patras Medical Oncology, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital of Patras Medical Oncology, 2 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 59 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 27 trials that are defined as “Not Applicable".